|Bid||79.33 x 800|
|Ask||79.37 x 800|
|Day's range||78.52 - 79.75|
|52-week range||69.10 - 95.19|
|Beta (5Y monthly)||0.65|
|PE ratio (TTM)||44.92|
|Earnings date||04 Feb 2021|
|Forward dividend & yield||0.98 (1.22%)|
|Ex-dividend date||03 Dec 2020|
|1y target est||93.71|
Baxter's (BAX) BioPharma Solutions business inks deal to advance commercial-scale production and increase access for the COVID-19 vaccine in the U.K. and European markets.
Baxter BioPharma Solutions announced an agreement with Novavax to provide sterile manufacturing services for its COVID-19 vaccine candidate.
Baxter International Inc. (NYSE:BAX), a leading global medical products company, will host a conference call to discuss its fourth-quarter 2020 financial results on Thursday, February 4, 2021 at 7:30 a.m. Central Time. To participate in this conference call please follow this link http://www.directeventreg.com/registration/event/5044187 to pre-register for the call and receive the call information.